Funding for this research was provided by:
S2 Therapeutics Inc
Received: 14 October 2020
Accepted: 13 January 2021
First Online: 23 January 2021
Ethics approval and consent to participate
: All animal experiments were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Experimental Animals (2011) and also with the protocols approved by the Institutional Animal Care and Use Committee of VeroScience, LLC.
: All authors have read and approved the final manuscript.
: The authors declare that they have no competing interests, however the authors are past or present employees of VeroScience LLC, a company that owns Cycloset, a dopamine agonist for the treatment of type 2 diabetes.